FDA Updates Regulations for Biological Products Amidst CBER and CDER Reorganization

Summary

The Food and Drug Administration (FDA) is updating its regulations to reflect the reorganization between the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER), including updated mailing address information and references to CDER. These changes aim to ensure consistency and accuracy in the regulations.